for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Gemphire Therapeutics Inc

GEMP.OQ

Latest Trade

0.50USD

Change

-0.03(-5.66%)

Volume

68,368

Today's Range

0.49

 - 

0.53

52 Week Range

0.42

 - 

2.50

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.53
Open
0.53
Volume
68,368
3M AVG Volume
5.84
Today's High
0.53
Today's Low
0.49
52 Week High
2.50
52 Week Low
0.42
Shares Out (MIL)
14.87
Market Cap (MIL)
7.44
Forward P/E
-0.91
Dividend (Yield %)
--

Latest Developments

More

Gemphire Therapeutics Reports Q2 Loss Per Share $0.20

Gemphire Therapeutics And Neurobo Pharmaceuticals Announce Merger

Gemphire Therapeutics And Neurobo Pharmaceuticals Announce Merger Agreement

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Gemphire Therapeutics Inc

Gemphire Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy. Gemcabene is liver-directed and inhibits apolipoprotein C-III (apoC-III) protein in the liver and may inhibit acetyl-CoA carboxylase (ACC) in the liver. Gemcabene blocks the overall production of hepatic triglycerides and cholesterol. Gemcabene has been tested as monotherapy and in combination with statins and other drugs in over 895 subjects, across approximately 18 Phase I and Phase II clinical trials. Gemcabene is used as an adjunctive therapy to reduce LDL-C, high-sensitivity C-reactive protein (hsCRP) and triglycerides.

Industry

Biotechnology & Drugs

Contact Info

PO Box 130235

+1.248.9806538

http://www.gemphire.com/

Executive Leadership

Charles L. Bisgaier

Chairman of the Board, Chief Scientific Officer

Steven R. Gullans

President, Chief Executive Officer, Director

Seth Reno

Chief Commercial Officer

Kenneth W. Kousky

Independent Director

Pedro Lichtinger

Independent Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.570

2017

-3.230

2018

-1.710

2019(E)

-0.550
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
3.63
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-134.03
Return on Equity (TTM)
-100.28

Latest News

BRIEF-Gemphire Therapeutics Reports Q1 Loss Per Share Of $0.58

* GEMPHIRE THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Gemphire Therapeutics Names Steven Gullans CEO

* GEMPHIRE THERAPEUTICS ANNOUNCES THE APPOINTMENT OF STEVEN GULLANS, PH.D., AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

BRIEF-Gemphire Therapeutics Reports Qtrly Loss Per Share $0.63

* GEMPHIRE THERAPEUTICS REPORTS FOURTH QUARTER AND FISCAL YEAR 2017 FINANCIAL RESULTS

BRIEF-Gemphire Therapeutics reports qtrly loss of $0.82/shr

* Gemphire Therapeutics Inc qtrly loss per share $0.82 Source: (http://bit.ly/2iaJuNF) Further company coverage:

BRIEF-Gemphire announces plans to advance gemcabene into phase 3 clinical development

* Gemphire announces plans to advance gemcabene into phase 3 clinical development

BRIEF-Gemphire Therapeutics Inc files mixed shelf of up to $175 million - SEC filing

* Gemphire therapeutics inc files mixed shelf of up to $175 million - SEC filing Source text: (http://bit.ly/2vRDX2x) Further company coverage:

BRIEF-Gemphire Therapeutics Inc posts Q2 net loss $0.99/shr

* Gemphire announces second quarter 2017 financial results and provides corporate update

BRIEF-Gemphire announces top-line data from royal-1 phase 2b clinical trial in hypercholesterolemic patients

* Gemphire announces top-line data from royal-1 phase 2b clinical trial in hypercholesterolemic patients

BRIEF-Gemphire enters into $15 mln term loan agreement with Silicon Valley Bank

* Gemphire enters into $15 million term loan agreement with silicon valley bank

BRIEF-Gemphire Therapeutics reports departure of CEO

* Gemphire Therapeutics announces departure of its chief executive officer Mina Sooch

BRIEF-Gemphire reports Q1 loss per share of $0.79

* Gemphire announces first quarter 2017 financial results and provides corporate update

BRIEF-Gemphire Therapeutics files for resale of up to 2.3 mln shares

* Gemphire Therapeutics files for resale of up to 2.3 million shares of co's common stock by selling stockholders - sec filing Source text - http://bit.ly/2p1yMht Further company coverage:

BRIEF-Adage Capital Partners GP LLC reports 5.85 pct passive stake in Gemphire Therapeutics

* Adage Capital Partners GP LLC reports 5.85 percent passive stake in Gemphire Therapeutics Inc as of March 10 - sec filing Source text : http://bit.ly/2mN2mmc Further company coverage:

BRIEF-Gemphire qtrly net loss attributable to common stockholders $7.2 mln

* Gemphire announces fiscal year 2016 financial results and provides corporate update

BRIEF-Gemphire Therapeutics announces $12.5 mln financing - SEC Filing

* Entered into securities purchase agreement for private placement with "a select group of accredited investors" - SEC Filing

BRIEF-Exchange Capital Management Inc reports 8.7 pct passive stake in Gemphire Therapeutics as of Feb 12, 2017

* Exchange Capital Management Inc reports a 8.7 percent passive stake in Gemphire Therapeutics inc as of feb 12, 2017 -sec filing Source text (http://bit.ly/2lyFeHV) Further company coverage:

BRIEF-Gemphire announces interim data from COBALT-1 clinical trial

* Gemphire announces interim LDL-C lowering data from COBALT-1 phase 2b clinical trial

BRIEF-Gemphire Therapeutics expands utility for Gemcabene

* Expanded utility for gemcabene demonstrate proof of concept efficacy in animal model of nonalcoholic steatohepatitis

BRIEF-Gemphire reports Q3 loss per share $0.56

* Gemphire announces third quarter 2016 financial results and provides corporate update

BRIEF-Gemphire therapeutics enrolls first patient in the COBALT-1 trial

* 1 trial investigating gemcabene in homozygous familial hypercholesterolemia

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up